Dr. Pranshu Mohindra, who joined the University of Maryland School of Medicine in 2014, is the lead radiologist for the acclaimed Mesothelioma and Thoracic Oncology Center. He works alongside thoracic surgeons and medical oncologists who also specialize in this rare and aggressive cancer most often caused by asbestos exposure.
They meet regularly to discuss each patient, personalizing mesothelioma treatment to best utilize the multimodality approach that has been so effective throughout the Greenebaum Cancer Center.
Those mesothelioma doctors include surgeon Dr. Joseph Friedberg and oncologist Dr. Christian Rolfo.
Mohindra’s role at Greenebaum is clinical and scientific. He works closely with pleural mesothelioma patients and with other researchers to develop novel treatments for all cancer patients.
Experience with the Latest Techniques
Mohindra is experienced in the latest radiation modalities.
His expertise includes the novel pencil-beam scanning proton therapy, intensity modulated proton therapy, intensity modulated radiation therapy, stereotactic body radiation therapy, stereotactic radiotherapy and image-guided brachytherapy.
He played a leading role in the initiation of his department’s MRI-guided brachytherapy program and is one of the few providers in the Washington, D.C., and Baltimore area with expertise in the brachytherapy procedures.
Proton therapy is a newer, precise form of radiation that treats a wide variety of solid tumors but is available only at select cancer centers around the country.
Part of Maryland’s Research Excellence
Mohindra often represents the school of medicine’s nationally recognized research efforts in radiation therapy.
One of his latest projects involves finding new ways to expand the use of proton therapy in the management of thoracic and lung malignancies, which includes mesothelioma.
“Proton therapy can better spare healthy tissue, which minimizes side effects and can help patients significantly,” he said.
His radiation oncology training included residencies at the University of Wisconsin and the Tata Memorial Centre in Mumbai, India.
Mohindra did one fellowship in head and neck cancers at Princess Margaret Hospital in Toronto, and another in global academic research at the University of Texas MD Anderson Cancer Center.
Leader of NHI-Sponsored Clinical Trials
Mohindra is heavily involved in early-stage clinical trials that study the latest radiation therapies.
He is the principal investigator of two National Cancer Institute-sponsored clinical trials, including one studying brain metastases from non-small cell lung cancer.
The University of Maryland nominated him for the Board of Directors at the Alliance for Clinical Trials in Oncology, which covers almost 10,000 cancer specialists at medical centers and hospitals across the United States and Canada.
As an associate professor at the University of Maryland, he is the director of research internships and has mentored several medical students who won national awards for research projects.